Trial
NCT03531827
Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Metastatic Castration Resistant Prostate Cancer
Intervention
enzalutamide
Why stopped
Study was closed for toxicity.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2022-07-12